Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Camu Camu extract
- Development stage
- Unknown
- Lead developer
- McGill University Health Centre
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Camu Camu extract (Camu CTM) is a natural prebiotic intervention derived from the Amazonian fruit *Myrciaria dubia*. It is being investigated by the McGill University Health Centre for its potential to reduce systemic inflammation and immune activation in people living with HIV who are on stable antiretroviral therapy (ART). The extract is rich in vitamin C and polyphenols, which are thought to modulate the gut microbiota, specifically by increasing the abundance of *Akkermansia muciniphila*. This modulation aims to strengthen the gut barrier, thereby reducing the translocation of microbial products like lipopolysaccharide (LPS) into the bloodstream, which is a key driver of chronic inflammation in HIV-infected individuals. The intervention is currently being evaluated in a Phase 2 pilot study to assess its impact on circulating LPS levels and gut microbiota composition.
- Brand names
- Camu CTM
- Other names
- Myrciaria dubia extractCamu Camu powder
Beyond the preview
Go deeper on Camu Camu extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Camu Camu extract.